Related Experiment Video
Updated: Aug 14, 2026
Isolation and Intravenous Injection of Murine Bone Marrow Derived Monocytes
Published on: December 27, 2014
Autologous bone marrow mononuclear cell transplantation in patients undergoing coronary artery bypass grafting
David Mocini1, Mario Staibano, Luca Mele
1Division of Cardiology, Cardiovascular Department, S. Filippo Neri Hospital, Rome, Italy. david.mocini@fastwebnet.it
Insights
Directly injecting autologous bone marrow mononuclear cells (aBM-MNCs) during coronary artery bypass grafting (CABG) is feasible and safe for myocardial infarction patients. Further research is needed to confirm efficacy in this patient group.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Surgical Innovation
Background:
- Autologous bone marrow mononuclear cell (aBM-MNC) transplantation shows promise for myocardial repair.
- Limited data exist on aBM-MNC transplantation in patients undergoing coronary artery bypass grafting (CABG).
Purpose of the Study:
- To evaluate the feasibility and safety of aBM-MNC transplantation in patients with recent myocardial infarction undergoing CABG.
Main Methods:
- 36 patients with recent myocardial infarction undergoing CABG were studied.
- 18 patients received CABG plus direct myocardial injection of aBM-MNCs; 18 served as controls.
- Cell transplantation involved injecting approximately 292 ± 232 x 10^6 aBM-MNCs into the infarct border zone.
Main Results:
- Transplanted patients had a higher troponin I peak post-CABG (1.65 ng/mL vs 0.64 ng/mL).
- No major transplant-related adverse events were observed.
- Transplanted patients showed improved left ventricular ejection fraction (0.46 to 0.51) and wall motion score index (1.71 to 1.42).
- Arrhythmia incidence was similar between groups.
Conclusions:
- Direct myocardial injection of aBM-MNCs during CABG is feasible and safe.
- Larger studies are required to establish the efficacy of this approach in CABG patients.
Background:
Recent studies have shown that autologous bone marrow mononuclear cell (aBM-MNC) transplantation can be effectively performed in human beings either by the coronary route or by endoventricular injections. However, scanty data are available for patients undergoing coronary artery bypass grafting (CABG). Accordingly, the aim of this study was to evaluate the feasibility and safety of aBM-MNC transplantation in patients with recent myocardial infarction undergoing CABG.
Methods And Results:
The study population included 36 consecutive patients with recent myocardial infarction (< 6 months) undergoing CABG. Eighteen patients (17 men, mean age 64 years) underwent CABG plus aBM-MNC transplantation, whereas 18 subjects undergoing conventional CABG (17 men, mean age 67 years) served as control subjects. Cell transplantation was performed by direct injections in the border zone of the recently infarcted area. An average number of 292 +/- 232 x 10(6) aBM-MNCs was injected in each patient. When compared with control subjects, transplanted patients showed higher values of troponin I peak after CABG (median values of 1.65 ng/mL vs 0.64 ng/mL, P < .001). No major transplant-related adverse event could be detected. During follow-up, transplanted patients had an improvement in left ventricular ejection fraction (from 0.46 to 0.51, P < .05) and wall motion score index (from 1.71 to 1.42, P < .01). The incidence of arrhythmias immediately after CABG and during follow-up was similar in the 2 groups.
Conclusions:
Our data support the idea that direct injection of aBM-MNCs in the myocardium during CABG is feasible and safe. Larger studies are needed to assess the efficacy of such an approach in patients undergoing CABG.
More Related Videos
11:37Protocol for MicroRNA Transfer into Adult Bone Marrow-derived Hematopoietic Stem Cells to Enable Cell Engineering Combined with Magnetic Targeting
Published on: June 18, 2018
08:05Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
Published on: March 17, 2020
